KRT5 and TP63 were selected as the biomarkers for distinguishing AC from SCC (subtypes of NSCLC), as well as novel molecular targets for targeted therapeutic agents [20, 21]. This evidence concerns the gene KRT5 and non-small cell lung carcinoma.